Galectin Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.37next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release (Form 10-Q) | 13 Nov 2026 |
| FY 2026 Annual Earnings Release (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Belapectin 2 mg/kg Per-Protocol Varices Reduction Annually49.3Target: 52.5% reduction
Cash and Cash Equivalents Quarterly14.1MTarget: Sufficient to fund operations through May 2027
Quarterly Net Loss Applicable to Common Stockholders Quarterly-5.1MTarget: Narrowing of losses
Watch Items
- FDA Type-C Meeting AlignmentTrigger: Written feedback or minutes from the Q2 2026 FDA meetingAction: Evaluate regulatory path forward, trial design requirements, and potential for accelerated approval pathways for belapectin.
- Cash Runway and Capital RaisingTrigger: Cash balance falling below $10 million or runway dropping below 9 monthsAction: Utilize the $32.5 million ATM program with H.C. Wainwright or draw down the remaining $10 million line of credit from the Chairman.
- Strategic Partnership AgreementsTrigger: Execution of a co-development or licensing deal for belapectinAction: Assess the financial terms, upfront payments, and milestone structures to offset late-stage clinical trial costs.
Research as of 19 Jun 2026